Article title: Treatment of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Focus on The Use of Tagraxofusp and Clinical Considerations
Authors: Naveen Pemmaraju, Yazan F. Madanat, David Rizzieri, Salman Fazal, Raajit Rampal, Gabriel Mannis, Eunice S Wang, James Foran, & Andrew Lane.
Journal: Leukemia & Lymphoma
DOI: https://doi.org/10.1080/10428194.2024.2305288
When the article was published online, an incorrection paragraph was included in the section “TAG as an induction therapy and bridge to SCT.”
Incorrect paragraph:
In clinical practice, many patients have been seen to have an early response to TAG, with little to no myelosuppression. This is in line with the results of the pivotal trial, where 57% of patients achieved a CR/CRc in cycle 1 after five doses, 14% had a CR/CRc after three or fewer doses, and the median time to first CR was 39 days (range 14–131) [27].
Correct paragraph:
In clinical practice, many patients have been seen to have an early response to TAG, with little to no myelosuppression. This is in line with the results of the pivotal trial, where 57% of patients achieved a CR/CRc in cycle 1 after five doses, 47% had a CR/CRc after only receiving up to three doses, and the median time to first CR was 39 days (range 14-131) [27].
Now, the paragraph has been updated and republished online.